Rheumatoid Arthritis + GLP-1 Medication Research
DISCLAIMER! GLP-1 Medications are NOT FDA-approved for Rheumatoid Arthritis.
Please talk to your doctor. Print out studies and bring them to your doctor. I am not associated with any organization and have no affiliation with anything I’m sharing. I collect these because I love science and am sharing them with you. I am not making any claims about GLP-1 medications by sharing this with you.
Key Studies and Direct Links
Allen Institute RA Pre-Symptomatic Study (2025)
Primary press release and full details on immune shifts, including Tfh17-like cells: https://alleninstitute.org/news/new-study-reveals-rheumatoid-arthritis-begins-long-before-symptoms-opening-door-to-prevention/
Related coverage: https://www.sciencedaily.com/releases/2025/11/251126095037.htm
Th17 Markers in Pre-Symptomatic RA Screening:
qPCR Th17 assay as biomarker (75% accuracy): https://www.precisionformedicine.com/hubfs/5014803/resources/pdf/PFM-Epiontis-13-Th17-Cells-via-qPCR-A-Diagnostic-Biomarker-for-...
Low Th17 levels predict RA: https://www.rheumatologyadvisor.com/news/low-levels-of-th17-cells-linked-to-developing-ra/
Th17/Treg ratio and markers: https://pubmed.ncbi.nlm.nih.gov/37667491/
Th17 cell markers panel: https://www.rndsystems.com/resources/cell-markers/immune-cells/helper-t-cells/th17-cell-markers
GLP-1 Impact on Th17 Cells:
Dulaglutide modulates Th17 in EAE model: https://pmc.ncbi.nlm.nih.gov/articles/PMC6479396/
Crosstalk GLP-1/Th17/Treg in autoimmunity: https://www.sciencedirect.com/science/article/abs/pii/S0196978122001000
Thyroid autoimmunity GLP-1/Th17 modulation: https://pmc.ncbi.nlm.nih.gov/articles/PMC12754808/
GLP-1RAs reduce Th17 differentiation: https://pmc.ncbi.nlm.nih.gov/articles/PMC12512578/
Immune modulation review: https://www.alliedacademies.org/articles/immune-modulation-with-glp1-receptor-agonists-a-breakthrough-in-treatment-31663.html
ACR 2025 GLP-1 in Rheumatic Disease:
Press release on RA flares reduction, semaglutide outcomes: https://rheumatology.org/press-releases/new-research-at-acr-convergence-2025-highlights-potential-of-glp-1-therapies-in-rheumati...
GLP-1RA effect on RA activity/CV risk: https://acrjournals.onlinelibrary.wiley.com/doi/10.1002/acr2.70103
ACR abstract on mortality reduction: https://acrabstracts.org/abstract/glp-1-receptor-agonists-reduce-mortality-and-cardiovascular-events-in-patients-with-rheumatoid...
RA flares with DMARDs + GLP-1: https://www.emjreviews.com/rheumatology/news/acr-2025-glp-1-drugs-reduce-rheumatoid-arthritis-flares/
